Ligustilide is the principal active constituent of Chuanxiong Rhizoma, possessing multiple pharmacological activities including anticoagulant, anti‑inflammatory and antioxidant effects. The content of ligustilide is calculated by multiplying the peak area of butylphthalide with a correction factor. The detection wavelength is set at 230 nm for butylphthalide and 330 nm for ligustilide; hence dual‑wavelength detection is required. This paper establishes a dual‑wavelength HPLC method for simultaneous determination of butylphthalide and ligustilide in Chuanxiong Rhizoma.
Chromatographic conditions follow the specifications laid down in the Chinese Pharmacopoeia (2025 Edition) with a C18 analytical column adopted for sample testing. In repeatability tests of standard reference solution, the RSD of butylphthalide retention time is 0.028%, the RSD of peak area is 0.291%, tailing factor equals 1.000 and theoretical plate number is 21604, which fully complies with the requirements of the 2025 Edition of Chinese Pharmacopoeia. This method can serve as a technical reference for routine quantitative analysis of ligustilide in Chuanxiong Rhizoma.
Instruments Used
Persee L820 High Performance Liquid Chromatograph configuration:
L820‑P22 Binary High‑Pressure Infusion Pump
L820‑A11 Autosampler
L820‑C11 Column Oven
L820‑D10 UV‑Vis Detector
LCWin‑V5.0 HPLC Workstation (Standard Version V5.0)
L820‑C304100001 Solvent Tray
